Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.

Abstract:

BACKGROUND:China is the most populous country in the world, with an annual birth cohort of approximately 16 million, requiring an average of 500 million vaccine doses administered annually. In China, over 30 domestic and less than 10 overseas vaccine manufacturers supply over 60 licensed vaccine products, representing a growing vaccine market mainly due to recent additions to the national immunization schedule, but data on post-marketing surveillance for adverse events following immunization (AEFI) are sparse. OBJECTIVES:To compare reporting rates for various categories of AEFI from China with other routine post-marketing surveillance programs internationally. METHODS:Systematic review of published studies reporting rates of AEFI by vaccine, category of reaction and age from post-marketing surveillance systems in English and Chinese languages. RESULTS:Overall AEFI reporting rates (all vaccines, all ages) in Chinese studies were consistent with those from similar international studies elsewhere, but there was substantial heterogeneity in regional reporting rates in China (range 2.3-37.8/100,000 doses). The highest AEFI reporting rates were for diphtheria-tetanus-pertussis whole-cell (DTwP) and acellular (DTaP) vaccines (range 3.3-181.1/100,000 doses for DTwP; range 3.5-92.6/100,000 doses for DTaP), with higher median rates for DTwP than DTaP, and higher than expected rates for DTaP vaccine. Similar higher rates for DTwP and DTaP containing vaccines, and relatively lower rates for vaccines against hepatitis B virus, poliovirus, and Japanese encephalitis virus were found in China and elsewhere in the world. CONCLUSIONS:Overall AEFI reporting rates in China were consistent with similar post-marketing surveillance systems in other countries. Sources of regional heterogeneity in AEFI reporting rates, and their relationships to differing vaccine manufacturers versus differing surveillance practices, require further exploration.

journal_name

Vaccine

journal_title

Vaccine

authors

Guo B,Page A,Wang H,Taylor R,McIntyre P

doi

10.1016/j.vaccine.2012.11.051

subject

Has Abstract

pub_date

2013-01-11 00:00:00

pages

603-17

issue

4

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(12)01665-9

journal_volume

31

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.

    abstract:BACKGROUND:Invasive pneumococcal disease and respiratory tract infections are both frequent and severe in patients with systemic lupus erythematosus (SLE). This study aimed to compare the immunological efficacy and safety of pneumococcal vaccination with the 23-valent polysaccharide (PPS) vaccine alone to a sequential ...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2017.07.094

    authors: Grabar S,Groh M,Bahuaud M,Le Guern V,Costedoat-Chalumeau N,Mathian A,Hanslik T,Guillevin L,Batteux F,Launay O,VACCILUP study group.

    更新日期:2017-09-05 00:00:00

  • Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.

    abstract::There is currently much interest in generating cytotoxic T lymphocyte (CTL) responses against tumor antigens as a therapy for cancer. In this study mouse fibroblasts (H-2(b)) were genetically modified to express a costimulatory B7.1 and a mature interleukin (IL)-18, and then loaded with an ovalbumin (OVA) epitope (SII...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.12.015

    authors: Chung SW,Cohen EP,Kim TS

    更新日期:2004-06-30 00:00:00

  • Influenza vaccination coverage in old people's home in Carmarthenshire, UK, during the winter of 1998/99.

    abstract::A mailed questionnaire survey was undertaken in old people's (nursing and residential) homes in Carmarthenshire, UK to determine the influenza vaccine uptake during the 1998/99 season. Out of the total 60 questionnaires circulated, response was received from 47 homes giving an overall response rate of 78%. Amongst the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00048-7

    authors: Gupta A,Morris G,Thomas P,Hasan M

    更新日期:2000-05-22 00:00:00

  • Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument.

    abstract:BACKGROUND AND OBJECTIVE:Parents' attitudes toward MMR vaccine and measles, mumps and rubella infections relate to their child's MMR status, therefore improving these attitudes is central to improving current suboptimal MMR uptake. However, no study has yet combined evidence-based, comprehensive and psychometrically va...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.12.030

    authors: Brown KF,Shanley R,Cowley NA,van Wijgerden J,Toff P,Falconer M,Ramsay M,Hudson MJ,Green J,Vincent CA,Kroll JS,Fraser G,Sevdalis N

    更新日期:2011-02-11 00:00:00

  • In search of the active PZP epitope in white-tailed deer immunocontraception.

    abstract::Native porcine zona pellucida (PZP) has been shown to be highly effective as an immunocontraceptive in white-tailed deer. However, the immunogenicity of PZP extracted from pig ovaries may vary from lot to lot and the extract has the potential of containing either viral or pathogenic material. Determination of the immu...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00195-0

    authors: Miller LA,Killian GJ

    更新日期:2002-06-21 00:00:00

  • Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?

    abstract::Outer membrane protein (OMP) vaccines are being developed against Neisseria meningitidis serogroup B which may provide protection against common circulating serotypes and serosubtypes in some countries. However, limited data is available in Europe from genosubtyping meningococci. We therefore undertook a retrospective...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00033-1

    authors: Clarke SC,Diggle MA,Mölling P,Unemo M,Olcén P

    更新日期:2003-06-02 00:00:00

  • Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.

    abstract:BACKGROUND:We have developed a new oral vaccine against enterotoxigenic Escherichia coli (ETEC), which is the most common cause of bacterial diarrhea in children in developing countries and in travelers. METHODS:The vaccine was tested for safety and immunogenicity alone and together with double-mutant heat-labile toxi...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2014.10.069

    authors: Lundgren A,Bourgeois L,Carlin N,Clements J,Gustafsson B,Hartford M,Holmgren J,Petzold M,Walker R,Svennerholm AM

    更新日期:2014-12-12 00:00:00

  • Recombinant congenic strains of mice: a new tool for the genetic dissection of efficacy and toxicity of adjuvants.

    abstract::The efficacy of immunization of a vaccine depends on an antigen, an adjuvant, and on the expression of multiple genes in the host. The responsiveness of various strains of mice to adjuvants is therefore dependent on their genetic background present as a complex, multigenic trait similarly as in man. We have recently d...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00528-5

    authors: Di Marco S,Moisan J,Boghdady ML,Skamene E,Radzioch D

    更新日期:2003-02-14 00:00:00

  • Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.

    abstract::Here, monophosphoryl lipid A (MPLA) and aluminum salt (Alum) were introduced into a hyaluronic acid (HA)-based combination vaccine adjuvant for hepatitis B vaccine (HBV). Although Alum is a well-known hepatitis B vaccine adjuvant that induces an enhanced humoral immune response, it cannot induce the cellular immune re...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.08.006

    authors: Moon SH,Shin EC,Noh YW,Lim YT

    更新日期:2015-09-11 00:00:00

  • Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs.

    abstract::The Ebola virus epidemic in West Africa proved to be the largest in the history of filovirus outbreaks, causing the World Health Organization to declare a public health emergency of international concern in August of 2014. In collaboration with domestic and international partners, the Biomedical Advanced Research and ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.10.111

    authors: Wolfe DN,Zarrabian AG,Disbrow GL,Espeland EM

    更新日期:2019-11-15 00:00:00

  • Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA.

    abstract::The RNA N-glycosidase ribosome inactivating proteins (RIPs) constitute a ubiquitous family of plant- and bacterium-derived toxins that includes the category B select agents ricin, abrin and shiga toxin. While these toxins are potent inducers of intestinal epithelial cell death and inflammation, very little is known ab...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.11.030

    authors: Neal LM,McCarthy EA,Morris CR,Mantis NJ

    更新日期:2011-01-17 00:00:00

  • The FAI protein of group C streptococci targets B-cells and exhibits adjuvant activity.

    abstract::We have demonstrated that the fibrinogen-albumin-IgG receptor of group C streptococci (FAI) targets B-cells in vivo. We exploited the targeting properties of FAI to improve the immune responses stimulated by soluble antigens administered by the mucosal route. Enhanced systemic and mucosal immune responses were observe...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.08.045

    authors: Schulze K,Goldmann O,Toppel A,Medina E,Guzmán CA

    更新日期:2005-02-03 00:00:00

  • Use of allicin as feed additive to enhance vaccination capacity of Clostridium perfringens toxoid in rabbits.

    abstract::The present study assessed the efficacy of Clostridium perfringens (C. perfringens) toxoid and/or allicin - as feed additive - in rabbits for preventing or minimizing the severity of infection with locally isolated strain of C. perfringens type A. Serum biochemical, immunological and pathological investigations were a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.02.073

    authors: Abu El Hammed W,Soufy H,El-Shemy A,Nasr SM,Dessouky MI

    更新日期:2016-04-12 00:00:00

  • Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

    abstract::The development of live attenuated vaccines, allowing for the safe and effective immunisation at mucosal surfaces, is a strategy of great interest for vaccinologists. The main advantage of this approach over conventional parenteral vaccines is the induction of strong mucosal immune responses, allowing targeting of the...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2003.12.033

    authors: Viret JF,Dietrich G,Favre D

    更新日期:2004-06-23 00:00:00

  • Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.

    abstract::Malaria represents a major global health problem but despite extensive efforts, no effective vaccine is available. Various vaccine candidates have been developed that provide protection in animal models, such as a gene gun-delivered DNA vaccine encoding the circumsporozoite protein (CSP) of Plasmodium berghei. A commo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.059

    authors: Bergmann-Leitner ES,Leitner WW,Duncan EH,Savranskaya T,Angov E

    更新日期:2009-09-18 00:00:00

  • Induction and maintenance of a phenotypically heterogeneous lung tissue-resident CD4+ T cell population following BCG immunisation.

    abstract::Tuberculosis (TB) is the biggest cause of human mortality from an infectious disease. The only vaccine currently available, bacille Calmette-Guérin (BCG), demonstrates some protection against disseminated disease in childhood but very variable efficacy against pulmonary disease in adults. A greater understanding of pr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.07.035

    authors: Bull NC,Kaveh DA,Garcia-Pelayo MC,Stylianou E,McShane H,Hogarth PJ

    更新日期:2018-09-05 00:00:00

  • Synthetic gonadotrophin-releasing hormone (GnRH) vaccines incorporating GnRH and synthetic T-helper epitopes.

    abstract::A vaccine against the gonadotrophin-releasing hormone (GnRH) is being developed as an immunological method for treatment of prostatic hypertrophy, based on the observation that active immunization against GnRH leads to the production of anti-GnRH antibodies which results in the shrinkage of the prostate gland. We have...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90077-b

    authors: Sad S,Chauhan VS,Arunan K,Raghupathy R

    更新日期:1993-01-01 00:00:00

  • Real world TB vaccines: clinical trials in TB-endemic regions.

    abstract::The first 4 years of the 21st century have been an exciting time for tuberculosis (TB) research. After more than a half-century, the first new vaccines for TB are beginning to enter human clinical trials. Based on advances in proteomics and genomics, new vaccine candidates are filling the preclinical pipeline and our ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2005.01.060

    authors: Doherty TM

    更新日期:2005-03-18 00:00:00

  • Vaccines in the era of genomics: the pneumococcal challenge.

    abstract::In this review we aim to provide the reader with an understanding of the capsular-based complexity of Streptococcus pneumoniae, one of the main limitations to current vaccine development. We then discuss the need for a new vaccine strategy based on proteic antigen candidates discovered in silico. Describing specifical...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2007.01.065

    authors: Barocchi MA,Censini S,Rappuoli R

    更新日期:2007-04-20 00:00:00

  • Data management of clinical trials during an outbreak of Ebola virus disease.

    abstract:INTRODUCTION:Clinical trial data management (DM) conducted during outbreaks like that of Ebola virus disease (EVD) in West Africa, 2014-2016, has to adapt to specific, unique circumstances. CTU Bern was asked to set up a safe data capture/management system that could be launched within a few weeks and cover two differe...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.09.094

    authors: Hossmann S,Haynes AG,Spoerri A,Diatta ID,Aboubacar B,Egger M,Rintelen F,Trelle S

    更新日期:2019-11-15 00:00:00

  • Achieving a "Grand Convergence" in global health by 2035.

    abstract::Historical evidence demonstrates the validity of the concept "Grand Convergence". The Lancet commission identified the major challenges facing low and lower middle income countries including the unfinished agenda, non-communicable diseases and injuries and an approach to funding and achieving these objectives along wi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.10.085

    authors: Mahmoud A

    更新日期:2017-01-20 00:00:00

  • Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.

    abstract:BACKGROUND:We assessed 2 investigational 11- and 12-valent vaccines, containing capsular polysaccharides of 10 serotypes as in the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and CRM197-conjugated capsular polysaccharides of serotypes 19A (11-valent) or 19A and 6A (12-valent)....

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2018.07.023

    authors: Carmona Martinez A,Prymula R,Miranda Valdivieso M,Otero Reigada MDC,Merino Arribas JM,Brzostek J,Szenborn L,Ruzkova R,Horn MR,Jackowska T,Centeno-Malfaz F,Traskine M,Dobbelaere K,Borys D

    更新日期:2019-01-03 00:00:00

  • Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.

    abstract::The induction of oral tolerance against disease-inducing antigens has emerged as a feasible strategy to prevent immunopathologies. In this study, we investigated the effect of oral immunization with whole antigens of Leishmania amazonensis promastigotes (LaAg) on murine cutaneous leishmaniasis. We found that two oral ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00427-4

    authors: Pinto EF,de Mello Cortezia M,Rossi-Bergmann B

    更新日期:2003-09-08 00:00:00

  • Selection bias in evaluating of influenza vaccine effectiveness: a lesson from an observational study of elderly nursing home residents.

    abstract::Selection bias is of critical concern in the study of influenza vaccine effectiveness when using an observational study design. This bias is attributable to the inherently different characteristics between vaccinees and non-vaccinees. The differences, which are related both to vaccination and signs of clinical disease...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.06.038

    authors: Fukushima W,Hayashi Y,Mizuno Y,Suzuki K,Kase T,Ohfuji S,Fujieda M,Maeda A,Hirota Y

    更新日期:2008-11-25 00:00:00

  • Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.

    abstract::Successes for neutralizing antibodies (nAbs) against the human immunodeficiency virus (HIV) include potent cross-clade neutralization of primary virus isolates by human neutralizing monoclonal antibodies (nmAbs) targeting conserved envelope epitopes. Furthermore, passively administered combinations of human nmAbs prev...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(02)00389-4

    authors: Ferrantelli F,Rasmussen RA,Hofmann-Lehmann R,Xu W,McClure HM,Ruprecht RM

    更新日期:2002-12-19 00:00:00

  • Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.

    abstract:BACKGROUND:The combined hexavalent diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis - Haemophilus influenzae type b conjugate vaccine (Infanrix hexa™; DTPa-HBV-IPV/Hib: GlaxoSmithKline Vaccines) induces robust responses to the HBV component when administered at 3, 5 and 11-12 months of age. We assesse...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.070

    authors: Avdicova M,Crasta PD,Hardt K,Kovac M

    更新日期:2015-05-28 00:00:00

  • Status and challenges of filovirus vaccines.

    abstract::Vaccines that could protect humans against the highly lethal Marburg and Ebola viruses have eluded scientists for decades. Classical approaches have been generally unsuccessful for Marburg and Ebola viruses and pose enormous safety concerns as well. Modern approaches, in particular those using vector-based approaches ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2006.11.037

    authors: Reed DS,Mohamadzadeh M

    更新日期:2007-03-01 00:00:00

  • Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.

    abstract::Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Precl...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.04.034

    authors: Hastings AK,Gilchuk P,Joyce S,Williams JV

    更新日期:2016-05-23 00:00:00

  • Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

    abstract::Development of effective new mucosal vaccine adjuvants has become a priority with the increase in emerging viral and bacterial pathogens. We previously reported that cationic liposomes complexed with non-coding plasmid DNA (CLDC) were effective parenteral vaccine adjuvants. However, little is known regarding the abili...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.05.009

    authors: Henderson A,Propst K,Kedl R,Dow S

    更新日期:2011-07-18 00:00:00

  • Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.

    abstract::Whole killed meningococci (Nm) and pertussis bacteria (Bp) were tested for mucosal immunogenicity and as mucosal adjuvants for an inactivated influenza virus vaccine given intranasally to unanaesthetized mice. Virus was given alone, or simply mixed with one of the bacterial preparations, in four doses at weekly interv...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00442-9

    authors: Berstad AK,Andersen SR,Dalseg R,Dromtorp S,Holst J,Namork E,Wedege E,Haneberg B

    更新日期:2000-03-17 00:00:00